Paper29617739
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
Dubberke ER and 5 others. Clin Infect Dis, 2018. Cited by 119 papers, by iCite.
Cite this record
ConductScience Library. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Papers, record 29617739. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29617739
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
- PubMed
- Publication types
- Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Biological Therapy | Major topic |
| Clostridioides difficile | Major topic |
| Clostridium Infections | Major topic |
| Enterocolitis, Pseudomembranous | Major topic |
| Microbiota | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Diarrhea | |
| Double-Blind Method | |
| Feces | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Recurrence | |
| Treatment Outcome | |
| Young Adult |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02299570 | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03817125 | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention | Background | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 30084881 | Reply to Million et al. | https://conductscience.org/library/papers/30084881 | PubMed |
| Comment in | 30084939 | Bacterial Cocktail to Treat Clostridium difficile Infection: Primum Non Nocere. | https://conductscience.org/library/papers/30084939 | PubMed |
Cited by70
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 119 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42332289 | Klebsiella genus as driver of human disease: from infections to non-communicable disorders. | Nat Rev Microbiol | 2026 | https://conductscience.org/library/papers/42332289 | PubMed |
| 42286373 | Efficacy Outcomes of Fecal Microbiota, Live-jslm in Preventing Recurrent Clostridioides difficile Infection from Seven Clinical Studies. | Infect Dis Ther | 2026 | https://conductscience.org/library/papers/42286373 | PubMed |
| 42042323 | Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome. | Infect Dis Rep | 2026 | https://conductscience.org/library/papers/42042323 | PubMed |
| 41809590 | Randomized double-blind clinical trial evaluating the effectiveness and safety of secondary prophylaxis with oral vancomycin versus placebo in the prevention of recurrence of clostridioides difficile infection in patients receiving systemic antibiotic therapy (PREVAN trial). | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/41809590 | PubMed |
| 41653256 | Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS. | Infect Dis Ther | 2026 | https://conductscience.org/library/papers/41653256 | PubMed |
| 41530607 | Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back. | Curr Gastroenterol Rep | 2026 | https://conductscience.org/library/papers/41530607 | PubMed |
| 41454672 | The role of gut microbiome in aging-associated diseases: where do we stand now and how technology will transform the future. | Gut Microbes | 2026 | https://conductscience.org/library/papers/41454672 | PubMed |
| 41245385 | Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update. | Ther Adv Gastroenterol | 2025 | https://conductscience.org/library/papers/41245385 | PubMed |
| 41239747 | Development of Peptide Glucosyltransferase Inhibitors With Comprehensive Coverage Across Clostridioides difficile Toxin B Sub-Types. | Biotechnol Bioeng | 2026 | https://conductscience.org/library/papers/41239747 | PubMed |
| 41230019 | Prevention of recurrent Clostridioides difficile infection by fecal microbiota, live-jslm (REBYOTA®) administered via colonoscopy: 6-month data from the single-arm phase IIIb CDI-SCOPE trial. | Ther Adv Gastroenterol | 2025 | https://conductscience.org/library/papers/41230019 | PubMed |
| 41158525 | Mechanisms of Clostridioides difficile glucosyltransferase toxins and their roles in pathology: insights and emerging therapeutic strategies. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/41158525 | PubMed |
| 40984900 | Microbiota-Based Therapies for Recurrent Clostridium difficile Infection: A Systematic Review of Their Efficacy and Safety. | Cureus | 2025 | https://conductscience.org/library/papers/40984900 | PubMed |
| 40901203 | Fecal microbiota transplantation as a therapeutic modality for recurrent Clostridioides difficile infection: reviewing efficacy, safety, mechanisms of action, and outcomes. | Ann Med Surg (Lond) | 2025 | https://conductscience.org/library/papers/40901203 | PubMed |
| 40619813 | Integrative systems biology approaches for analyzing microbiome dysbiosis and species interactions. | Brief Bioinform | 2025 | https://conductscience.org/library/papers/40619813 | PubMed |
| 40321366 | Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial. | Ther Adv Gastroenterol | 2025 | https://conductscience.org/library/papers/40321366 | PubMed |
| 40177588 | Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study. | Open Forum Infect Dis | 2025 | https://conductscience.org/library/papers/40177588 | PubMed |
| 40142848 | Operationalizing Team Science at the Academic Cancer Center Network to Unveil the Structure and Function of the Gut Microbiome. | J Clin Med | 2025 | https://conductscience.org/library/papers/40142848 | PubMed |
| 40046540 | Antibiotic-Associated Diarrhea Beyond C. Difficile: A Scoping Review. | Brown J Hosp Med | 2023 | https://conductscience.org/library/papers/40046540 | PubMed |
| 39944364 | Causal role of the gut microbiome in certain human diseases: a narrative review. | eGastroenterology | 2024 | https://conductscience.org/library/papers/39944364 | PubMed |
| 39821840 | Management of Recurrent Clostridioides difficile Infection (rCDI): A Systematic Literature Review to Assess the Feasibility of Indirect Treatment Comparison (ITC). | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/39821840 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29617739
GET https://conductscience.org/api/papers/v1/29617739/cited_by?page=2